Clinical Trials Logo

Clinical Trial Summary

The study would make it possible to document more explicitly the evolution of antibody titers at following a non-public vaccination over a large post-vaccination period in the French population . Analysis of real-life data would enhance knowledge of vaccine response kinetics It would be useful to identify possible early declines requiring doses Similarly, by analyzing antibody kinetics by age, sex, and vaccination status, the would be possible to determine whether there are differences in the immune response between these different sub-groups. In addition, it would provide additional information to assess the real impact of these non-public vaccines in public health and guide vaccine policies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06373510
Study type Interventional
Source CerbaXpert
Contact Barbara Perniconi
Phone 0671296728
Email bperniconi@cerbaresearch.com
Status Not yet recruiting
Phase N/A
Start date June 20, 2024
Completion date April 3, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT04109833 - Early Antibiotic Therapy and Vaccination
Completed NCT05043168 - Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination
Recruiting NCT05563753 - Early Antibiotic Therapy and Vaccinations in Preterm Infants
Completed NCT05160766 - Assessing Immune Response of Different COVID-19 Vaccines in Older Adults Phase 2
Not yet recruiting NCT06098703 - CARD for Community Pharmacy Vaccinations N/A
Recruiting NCT06023056 - Hepatitis B Vaccination After Neonatal Surgery
Withdrawn NCT05672654 - Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients N/A
Completed NCT04934215 - Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.
Recruiting NCT06294262 - Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine Phase 1/Phase 2